Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 2Carcinoma, Intraductal, Noninfiltrating 1Breast Carcinoma In Situ 1

Interventions

Cyclophosphamide 361Trastuzumab 352Paclitaxel 304Docetaxel 272Capecitabine 222Letrozole 221Carboplatin 185Doxorubicin 181Tamoxifen 157Radiotherapy 154Epirubicin 145Fulvestrant 143Anastrozole 139Surveys and Questionnaires 133Exercise 128pertuzumab 113Vinorelbine 110Blood Specimen Collection 109exemestane 106palbociclib 104Bevacizumab 104pembrolizumab 98Magnetic Resonance Spectroscopy 97Albumin-Bound Paclitaxel 87Gemcitabine 84Drug Therapy 83Lapatinib 78130-nm albumin-bound paclitaxel 72Neoadjuvant Therapy 71Cisplatin 69

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Breast Neoplasms × telapristone acetate × Clear all
NCT02314156 2023-02-22

Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy

Northwestern University

Phase 2 Completed
67 enrolled 14 charts
Breast

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT01800422 2020-01-18

Oral CDB-4124 vs. Placebo in Stage I-II Primary Breast Cancer

Northwestern University

Phase 2 Unknown
50 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡